<DOC>
	<DOCNO>NCT02587104</DOCNO>
	<brief_summary>A single-centered , non-randomized study approximately 20 subject see 12 week , receive EpiFix plus standard care . Safety effectiveness monitor throughout study .</brief_summary>
	<brief_title>dHACM In Treatment Diabetic Foot Ulcers</brief_title>
	<detailed_description>Approximately 20 subject enrol study . Subjects see to12 week unless 100 % epithelialization index wind two subsequent heal confirmation visit achieve prior week 12 . Each subject receive weekly application EpiFix plus standard care 100 % epithelialization achieve . The subject evaluate efficacy safety course trial .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Subject DFU meet follow requirement : Wound diabetic origin Located dorsal plantar surface foot Size range 1 25 cm2 ( Debridement do prior measurement treatment , clinically indicate ) Open minimum 30 day prior treatment ( Day 0 ) Failure prior treatment heal wound ( ≤25 % wound area reduction 14 consecutive day offload moist wound therapy immediately prior treatment Day 0 ) 2 . Affected limb must demonstrate adequate circulation , demonstrate one test list ( complete &lt; 60 day prior Day 0 ) Dorsum transcutaneous oxygen test ( TcPO2 ) result ≥30mmHg ; ABIs result ≥0.7 ≤1.2 ; Doppler arterial waveform , triphasic biphasic ankle affect foot 3 . General Subject Characteristics : Age 18 old Type 1 2 Diabetic ( criteria diagnosis diabetes mellitus per ADA ) Willing able provide consent participate procedure necessary complete study Females childbearing potential must willing use acceptable method contraception ( birth control pill , barrier , abstinence ) 1 . DFUs meeting criterion : NonIndex wound within 2 cm index DFU Active infection index DFU Index DFU great one year duration without intermittent closure DFU possible nonrevascularizable surgical site Known suspect local skin malignancy index diabetic ulcer Index DFU treat biomedical topical growth factor within previous 30 day . Study ulcer previously treat tissue engineer material ( e.g . Apligraf® Dermagraft® ) , EpiFix® , scaffold material ( e.g . Oasis® , MatriStem® ) within last 30 day 2 . Subjects follow lab value Day 0 : HbA1C ≥ 12 % time within previous 60 day Serum Creatinine ≥ 3.0mg/dl within last 6 month 3 . Therapy Related Exclusions : Subjects previously currently enrol study Subjects treat investigational drug ( ) investigational therapeutic device ( ) within 30 day Subjects currently receive radiation therapy chemotherapy Currently treat antibiotic 4 . Other Active Charcot deformity major structural abnormality foot Known allergy Gentamicin sulfate Streptomycin sulfate Subjects diagnose autoimmune connective tissue diseases Any pathology would limit blood supply compromise heal Known history poor compliance medical treatment Subjects know pregnant , plan become pregnant , breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Foot Diseases</keyword>
	<keyword>Foot Ulcer</keyword>
</DOC>